Contract Research Organizations

What CROs Do

A contract research organization conducts scientific studies on behalf of clients who lack the facilities, expertise, or willingness to do the work in-house. In preclinical pharmaceutical development, this means CROs house the animals, employ the technicians, run the studies, and deliver the data.

The pharmaceutical company designs the drug. The CRO tests it on beagles.

This arrangement serves multiple purposes. It provides economies of scale — a single CRO facility can run studies for dozens of clients simultaneously. It provides regulatory expertise — CROs specialize in Good Laboratory Practice (GLP) compliance. And it provides distance — the pharmaceutical company's name does not appear on the facility door where dogs are gavaged, bled, and euthanized.

The Major Players

• Charles River Laboratories — the largest CRO in the world, with approximately $4 billion in annual revenue. Headquartered in Wilmington, Massachusetts. Operates preclinical testing facilities globally. Also breeds its own research animals, including rodents and primates, though it sources beagles primarily from Marshall BioResources.
• Labcorp Drug Development (formerly Covance) — a division of Laboratory Corporation of America. One of the oldest and largest preclinical CROs. Operates facilities in the US, UK, and Asia. The Covance name became synonymous with animal testing protests in the 2000s; the rebranding to Labcorp was, in part, a response.
• Inotiv — a mid-sized CRO that expanded rapidly through acquisitions, including the purchase of Bioanalytical Systems and Envigo's non-breeding research services. Inotiv's financial filings reveal a telling concentration of revenue: a single unnamed client accounts for 16.6% of total revenue. This dependency on a small number of pharmaceutical clients is common across mid-tier CROs.
• SNBL (Shin Nippon Biomedical Laboratories) — a Japanese CRO with US operations, specializing in non-human primate and canine studies. Serves the Japanese and US pharmaceutical markets.
• Altasciences — a Canadian-American CRO that maintains approximately 700 canines and conducts over 700 studies per year. Altasciences offers integrated services from preclinical through early clinical development, a model that keeps the client within a single CRO ecosystem.

The Intermediary Function

CROs exist at the intersection of pharmaceutical companies, regulatory agencies, and animal suppliers. The flow is straightforward:

1. 1.A pharmaceutical company develops a drug candidate.
2. 2.Regulatory guidelines ([ICH](/wiki/the-regulatory-framework), OECD, FDA) require specific animal studies before human trials.
3. 3.The pharmaceutical company contracts a CRO to conduct those studies.
4. 4.The CRO acquires beagles from a breeder (usually Marshall).
5. 5.The CRO performs the studies, collects the data, writes the reports.
6. 6.The pharmaceutical company submits the data to regulatory agencies.

At no point does the pharmaceutical company need to touch, house, dose, or kill a dog. The CRO handles all of it. This structural separation allows pharmaceutical companies to state, accurately, that they do not conduct animal testing — they contract it out.

Revenue and Dependency

The preclinical testing market is substantial. CROs collectively generate tens of billions in annual revenue, with animal testing representing a significant but declining proportion of total services as in vitro and computational methods grow.

Revenue concentration creates vulnerability. Inotiv's disclosure that 1 client represents 16.6% of revenue means that losing that client could threaten the company's financial viability. This dynamic gives large pharmaceutical companies significant leverage over CRO practices — and creates incentives for CROs to accommodate client preferences, including on animal welfare standards.

Conversely, CROs with fewer competitors can command premium pricing. As smaller CROs consolidate or close, the remaining players gain pricing power. The closure of Envigo's breeding operations and other facilities has tightened the market.

Oversight

CROs are subject to the same regulatory framework as any entity using animals in research:

• USDA licensing and inspection under the Animal Welfare Act
• AAALAC accreditation — voluntary but expected by major pharmaceutical clients
• GLP compliance — FDA 21 CFR Part 58, enforced through periodic inspections
• IACUC oversight — each facility maintains its own committee

The quality and independence of this oversight varies dramatically across CROs. Large, well-resourced facilities like Charles River maintain robust compliance programs. Smaller or rapidly growing CROs may cut corners — as the Envigo case demonstrated when thousands of beagles were found in squalid conditions at a facility that was, on paper, fully licensed and compliant.

Sources

1. 1.CRO Financial Filings, 2023-2024. SEC filings and annual reports for Charles River Laboratories, Inotiv, and Labcorp Drug Development, including revenue breakdowns and client concentration disclosures.
2. 2.Industry Analysis, 2024. Market analysis of the preclinical contract research sector, including competitive dynamics, consolidation trends, and pricing.